Roche (OTCMKTS:RHHBY) Sets New 52-Week High – Here’s Why

Roche Holding AG (OTCMKTS:RHHBY)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $60.22 and last traded at $60.10, with a volume of 1283862 shares changing hands. The stock had previously closed at $58.51.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group upgraded Roche from a “sell” rating to a “hold” rating in a report on Thursday, January 15th. JPMorgan Chase & Co. upgraded shares of Roche from an “underweight” rating to a “neutral” rating in a report on Monday, December 8th. Jefferies Financial Group downgraded shares of Roche from a “hold” rating to a “moderate sell” rating in a research report on Monday, October 27th. TD Cowen reaffirmed a “hold” rating on shares of Roche in a research report on Tuesday, February 10th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Roche from a “sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $57.00.

Roche Price Performance

The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.80. The company has a fifty day moving average price of $54.02 and a two-hundred day moving average price of $46.91.

Hedge Funds Weigh In On Roche

Hedge funds and other institutional investors have recently made changes to their positions in the company. Boston Common Asset Management LLC raised its position in Roche by 1.9% during the third quarter. Boston Common Asset Management LLC now owns 368,553 shares of the company’s stock worth $15,049,000 after acquiring an additional 6,720 shares in the last quarter. Altrius Capital Management Inc increased its stake in shares of Roche by 4.0% during the 3rd quarter. Altrius Capital Management Inc now owns 198,278 shares of the company’s stock worth $8,290,000 after purchasing an additional 7,659 shares during the last quarter. Bard Financial Services Inc. raised its holdings in shares of Roche by 1.3% in the 3rd quarter. Bard Financial Services Inc. now owns 138,650 shares of the company’s stock valued at $5,797,000 after purchasing an additional 1,800 shares during the period. Rhumbline Advisers lifted its stake in Roche by 1.1% in the 2nd quarter. Rhumbline Advisers now owns 108,480 shares of the company’s stock valued at $4,422,000 after purchasing an additional 1,228 shares during the last quarter. Finally, Meritage Portfolio Management bought a new position in Roche during the fourth quarter worth about $4,372,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.